Otsuka Holdings Co., Ltd.(4578) News

Otsuka Receives FDA Accelerated Approval for VOYXACT(sibeprenlimab-szsi)

Sibeprenlimab Phase 3 Data Presented at American Society of Nephrology Kidney Week 2025

Consolidated Financial Results for the Nine-Month Period Ended September 30, 2025 [IFRS]

Integrated Report 2025

(Progress of Disclosure)Notice of Completion of Share Transfer of Equity-Method Affiliate

Otsuka and Lundbeck Receive Complete Response Letter from U.S. FDA for sNDA of REXULTI

Notice Regarding Partial Amendment to “Notification of Change of Equity Method Affiliate (Transfer of Shares)”

Consolidated Financial Results for the Six-Month Period Ended June 30, 2025 [IFRS]

Notice of Payment of Interim Dividend and Revision of Annual Dividend Forecast

Notice Regarding Revisions of Consolidated Results Forecast for the first half of FY2025

Notification of Change of Equity Method Affiliate (Transfer of Shares)

Otsuka and Lundbeck Issue Statement on U.S. FDA Advisory Committee Meeting on REXULTI for the Treatment of Adults with PTSD

Otsuka Sibeprenlimab Phase 3 Data Show a Statistically Significant and Clinically Meaningful Proteinuria Reduction for the Treatment of IgAN

Otsuka Announces FDA Acceptance and Priority Review of BLA for Sibeprenlimab in the Treatment of IgAN

Notice Regarding Change in Major Shareholders

Consolidated Financial Results for the Three-Month Period Ended March 31, 2025 [IFRS]

(Correction)Partial Correction to Otsuka Pharmaceutical Factory,Inc. and ICU Medical Announce the Establishment of Joint Venture

Notice Concerning Completion of Payment for Disposal of Treasury Shares as Restricted Stock Compensation

Notification of Completion of Share Repurchase and Number of Treasury Stock to be Cancelled

[Delayed] Corporate Governance Report